This analysis explores the principal regulatory concerns linked to nanomedicines and gene vaccines, including the complexities involved and the perspectives on how to navigate them. In the realm of nanomedicines, ensuring the safety of nanomaterials is paramount due to their unique characteristics and potential interactions with biological systems. Regulatory bodies are actively formulating guidelines and standards to assess the safety and risks associated with nanomedicine products, emphasizing the need for standardized characterization techniques to accurately gauge their safety and effectiveness. Regarding gene vaccines, regulatory frameworks must be tailored to address the distinct challenges posed by genetic interventions, necessitating special considerations in safety and efficacy evaluations, particularly concerning vector design, target specificity, and long-term patient monitoring. Ethical concerns such as patient autonomy, informed consent, and privacy also demand careful attention, alongside the intricate matter of intellectual property rights, which must be balanced against the imperative of ensuring widespread access to these life-saving treatments. Collaborative efforts among regulatory bodies, researchers, patent offices, and the private sector are essential to tackle these challenges effectively, with international cooperation being especially crucial given the global scope of nanomedicine and genetic vaccine development. Striking the right balance between safeguarding intellectual properties and promoting public health is vital for fostering innovation and ensuring equitable access to these ground-breaking technologies, underscoring the significance of addressing these regulatory hurdles to fully harness the potential benefits of nanomedicine and gene vaccines for enhancing healthcare outcomes on a global scale. STATEMENT OF SIGNIFICANCE: Several biomaterials are being proposed for the development of nanovaccines, from polymeric micelles, PLGA-/PEI-/PLL-nanoparticles, solid lipid nananoparticles, cationic lipoplexes, liposomes, hybrid materials, dendrimers, carbon nanotubes, hydrogels, to quantum dots. Lipid nanoparticles (LNPs) have gained tremendous attention since the US Food and Drug Administration (FDA) approval of Pfizer and Moderna's COVID-19 vaccines, raising public awareness to the regulatory challenges associated with nanomedicines and genetic vaccines. This review provides insights into the current perspectives and potential strategies for addressing these issues, including clinical trials. By navigating these regulatory landscapes effectively, we can unlock the full potential of nanomedicine and genetic vaccines using a range of promising biomaterials towards improving healthcare outcomes worldwide.

In the clearest definition, phytochemicals are described as substances that plants generate. However, the phrase is frequently employed to refer to plant-derived compounds that might have biological effects but are not necessarily nutrients. Contrary to essential nutrients, phytochemicals are not necessary for cytological development, but they are crucial in protecting neuronal cells against reactive oxygen species and inflammatory processes that are linked to age-independent neuropsychiatric abnormalities. Millions of individuals suffer from obsessive-compulsive disorder (OCD), an anxiety affliction. This abnormality comprises sequence of undesirable emotions and anxieties (obsessions) that lead to repetitious actions (compulsions) as a symptom of the disorder. These compulsive thoughts and behaviors disrupt routine life and create severe discomfort. The suggested therapies at present include medications like, psychotherapy and pharmacotherapy. Besides these remedies for OCD, utilization of phytochemicals have widely been explored for its anti-OCD effects. This chapter gives an in-depth understanding about the various herbal plants and phytochemicals that have the potential as anti-OCD agents and its underlying mechanism of action against OCD. <!----> <!----> <!----> <!---->